|Study Description:||The goal of this clinical research study is to learn if the combination of 2 |
drugs (GSK2118436 and GSK1120212) can help to control melanoma. The safety of
this drug combination will also be studied.
GSK2118436 is designed to block the mutated BRAF protein. This mutation is
only found in moles of the skin and in melanoma cells. By blocking the protein,
the drug may slow the growth of or kill cancer cells that have the protein.
GSK1120212 is designed to block certain proteins that cause cancer cells to
grow and multiply. This may cause the cancer cells to die.